ARTICLE | Company News
Sosei Co. Ltd., Mitsubishi Pharma deal
November 8, 2004 8:00 AM UTC
Sosei received an exclusive worldwide license from Mitsubishi to develop and commercialize bifemelane (SON-216), a small molecule to treat ADHD. Mitsubishi retains co-promotion rights in Japan, where ...